AI-generated analysis. Always verify with the original filing.
Inventiva S.A. reported 2025 full year revenues of €4.5 million, a net loss of €354.1 million, cash runway to mid-Q1 2027, and NATiV3 Phase 3 topline results expected Q4 2026.
Event Type
Disclosure
Voluntary
Variant
6-K
Current Report on Form 6-K
| Metric | Value | Basis |
|---|---|---|
| Revenues | $4.5K | |
| Other income | $3.4K | |
| Research and development expenses | $-87.0K | |
| Marketing – business development expenses | $-5.0K | |
| General and administrative expenses | $-47.9K | |
| Other operating income (expenses) | $-9.0K | |
| Net operating loss | $-141.0K | |
| Net financial loss | $-212.8K | |
| Share of net loss - Equity method | $-350.00 | |
| Income tax | $-22.00 | |
| Net loss for the period | $-354.1K | |
| Basic/diluted loss per share | $-1.90 |
Renee Aguiar-Lucander
Effective: 2025-06
Jason Campagna, MD, PhD
Effective: 2025-07
Martine Zimmermann, PharmD
Effective: 2025-08
Andrew Obenshain
Effective: 2025-10
Nazira Arma
Effective: 2025-12